相关实验视频

Updated: May 28, 2025

A Comprehensive Procedure to Evaluate the In Vitro Performance of the Putative Hemangioblastoma Neovascularization Using the Spheroid Sprouting Assay

A Comprehensive Procedure to Evaluate the In Vitro Performance of the Putative Hemangioblastoma Neovascularization Using the Spheroid Sprouting Assay

Published on: April 12, 2018

在婴儿血瘤管理中纳米技术

Muhammad Sulaiman¹, Endang Lukitaningsih¹, Ronny Martien¹

¹Doctoral Program (MS), Faculty of Pharmacy, Department of Pharmaceutical Chemistry (EL, RM), Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, Indonesia; Department of Dermatology and Venereology (YWW, RD), Faculty of Medicine, Public Health and Nursing, Gadjah Mada University, Yogyakarta, Indonesia.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG

|February 12, 2025

概括

纳米粒子技术为治疗婴儿血管瘤 (IH) - - 一种常见的婴儿血管瘤 - - 提供了有前途的新途径. 这种方法增强了药物输送,潜在地提高了疗效,减少了副作用,从而改善了IH的管理.

科学领域:

生物医学工程生物医学工程
纳米技术纳米技术
皮肤病学皮肤病学

背景情况:

婴儿血瘤 (IH) 是婴儿最常见的良性血管瘤.
虽然许多IH病例自发地消失,但并发症和美容问题需要治疗.
目前的治疗方法包括口服/局部药物,激光疗法和手术.

研究的目的:

探索纳米粒子技术在婴儿血管瘤治疗中的潜力.
审查纳米技术如何提高IH的药物输送.
讨论纳米粒子选择和IH治疗的配方.

主要方法:

审查现有的研究纳米粒子为IH基于治疗的现有研究.
分析影响纳米粒子选择的因素 (例如药物兼容性,向).
讨论改善治疗结果的配方优化.

主要成果:

纳米颗粒药物递送系统可以改善治疗剂的透和吸收.
有针对性的治疗可以最大限度地减少与IH治疗相关的全身副作用.
纳米技术提供了减少治疗剂量和持续时间的潜力.

结论:

纳米粒子技术为提高婴儿血管瘤治疗效率提供了一个有希望的战略.
精心选择和制定纳米粒子对于成功的IH治疗至关重要.
对基于纳米粒子的方法的进一步研究可能会彻底改变IH管理.

关键词:

血瘤 (hemangioma) 是一种流动性疾病.纳米颗粒是一种纳米粒子.纳米技术是纳米技术.药品制剂制剂制剂制剂制剂制剂制品制品制品制品制品制品制品制品制品制品制品

更多相关视频

Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation

Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation

Published on: December 15, 2010

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

相关概念视频

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...